Clinical Trial

Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To determine the effect of neoadjuvant atezolizumab alone or in combination with other immune modulating agents on T-cell infiltration in advanced SCCHN. To determine the impact of neo-adjuvant immunotherapy on surgical outcomes.
Protocol Amendment History 3 changes
critical Enrollment closed, study ongoing 2026-08-12
notable Primary completion moved earlier: 2028-06-30 -> 2027-07-31 2026-08-12
minor Completion moved earlier: 2028-06-30 -> 2027-07-31 2026-08-12
Trial Details
NCT Number NCT03708224
Lead Sponsor Alain Algazi
Collaborators: Genentech, Inc., American Head and Neck Society
Conditions Cancer, Carcinoma, Squamous Cell Carcinoma, Head and Neck Cancer
Enrollment 55 participants
Start Date 2019-03-08
Primary Completion 2027-07-31 (estimated)
Study Completion 2027-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-11